In this retrospective study, we have included a significant sample of very LS of NSCLC without EGFR mutations or ALK/ROS1 translocations, and with a median OS of 36 months, at nine hospitals in Madrid. This evidence concerns the gene ALK and non-small cell lung carcinoma.